Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology.
Methods. 2017 Jul 23;:
Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with (177)Lu.
Pharm Res. 2016 Dec 16;
Depot system for controlled release of gold nanoparticles with precise intratumoral placement by permanent brachytherapy seed implantation (PSI) techniques.
Int J Pharm. 2016 Nov 3;:
Development and preclinical studies of (64)Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT.
MAbs. 2016 Nov 4;:0
(111)In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after intratumoral injection.
Nucl Med Biol. 2016 Aug 24;43(12):818-826
Monte-Carlo N-Particle (MCNP) Modeling of the Cellular Dosimetry of 64Cu - Comparison with MIRDcell S-Values and Implications for Studies of its Cytotoxic Effects.
J Nucl Med. 2016 Sep 22;
Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
Mol Pharm. 2015 Nov 2;12(11):3963-72
Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
Nucl Med Biol. 2016 Jul 21;43(10):635-641
Stability and Biodistribution of Thiol-Functionalized and (177)Lu-Labeled Metal Chelating Polymers Bound to Gold Nanoparticles.
Biomacromolecules. 2016 Mar 25;